newsfilter
← Earnings
Earnings Releases·

CG Oncology — Third Quarter 2026 Earnings Summary

CG Oncology reported a net loss of $56.9 million for the third quarter of 2026, driven by increased research and development expenses related to clinical trials and headcount. The company holds $984.5 million in cash, cash equivalents, and marketable securities, which is sufficient to fund operations through 2029. Key business updates include the anticipation of Phase 3 topline data for the PIVOT-006 trial in November 2026 and 12-month data for the BOND-003 and CORE-008 trials in December 2026. Additionally, the company expects to complete its Biologics License Application submission for BCG-unresponsive non-muscle invasive bladder cancer in the fourth quarter of 2026.

Company
CG ONCOLOGY INC
Sector
Healthcare
Industry
Biotechnology